Intercept Pharmaceuticals

Live disease
#FDA #Fibrosis #GlobalData #Intercept Pharmaceuticals #Liver disease #Regulatory #Trial data #United States

First drug for NASH under second FDA review

Intercept Pharmaceuticals’ obeticholic acid (OCA) could be first drug to be approved in the US for non-alcoholic steatohepatitis (NASH), according to analysts GlobalData.  The Food and Drug Administration (FDA) accepted the company’s resubmission of its new drug application (NDA) for OCA in patients with pre-cirrhotic liver fibrosis due to NASH… Read More

#News #Regulatory